DeepMed Research

NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD

🇸🇬Singapore

Country: 🇸🇬Singapore

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells

Phase 1

Conditions: Neuroblastoma Recurrent

Interventions: Biological: Anti-GD2 in combination with NK cells

First Posted Date: 2017-08-08

Last Posted Date: 2018-03-30

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 5

Registration Number: NCT03242603

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

TenTaTorch: Venepuncture Made Easy

Not Applicable

Conditions: Vein Thrombosis
Vein Disease
Vein; Tortuous
Vein Collapse

Interventions: Other: Conventional
Device: Veinlite
Device: TenTaTorch

First Posted Date: 2017-06-28

Last Posted Date: 2020-10-28

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 120

Registration Number: NCT03202238

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Metformin and Simvastatin in Addition to Fulvestrant

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Metformin/Simvastatin/Fulvestrant

First Posted Date: 2017-06-20

Last Posted Date: 2017-06-20

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 28

Registration Number: NCT03192293

Locations: 🇸🇬
National University Hospital Singapore, Singapore, Singapore

A First-in-Human Study of PRL3-ZUMAB

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: PRL3-ZUMAB

First Posted Date: 2017-06-19

Last Posted Date: 2019-09-03

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 38

Registration Number: NCT03191682

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Vinorelbine

First Posted Date: 2017-06-15

Last Posted Date: 2018-03-29

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 36

Registration Number: NCT03188159

Locations: 🇸🇬
National University Hospital, Singapore, Singapore
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Australia

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis

Phase 1

Active, not recruiting

Conditions: Peritoneal Carcinomatosis

Interventions: Drug: Oxaliplatin
Drug: Oxaliplatin & Nivolumab

First Posted Date: 2017-06-01

Last Posted Date: 2024-05-29

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 21

Registration Number: NCT03172416

Locations: 🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
🇧🇪
Ghent University Hospital, Ghent, Belgium
🇸🇬
National University Hospital, Singapore, Singapore

Clinical and Functional Outcomes at 2 Years of 4-strand Versus 5-strand Hamstring Autograft in Anterior Cruciate Ligament Reconstruction

Not Applicable

Conditions: Physical Activity

Interventions: Procedure: Strands of Hamstring Autograft in ACL reconstruction

First Posted Date: 2017-05-31

Last Posted Date: 2017-05-31

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 80

Registration Number: NCT03171532

Locations: 🇸🇬
National University Health System, Singapore, Singapore

Phase II Study of Single Agent Lenvatinib

Phase 2

Conditions: Breast Cancer

Interventions: Drug: lenvatinib

First Posted Date: 2017-05-30

Last Posted Date: 2017-06-16

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 30

Registration Number: NCT03168074

Locations: 🇸🇬
Nationa University Hospital, Singapore, Singapore

Pulsed Electromagnetic Field (PEMF) Systems to Promote the Maintenance of Bone and Muscle

Not Applicable

Conditions: Muscle Loss Post Anterior Cruciate Ligament Reconstruction

Interventions: Device: Pulsed Electromagnetic Field Therapy
Device: Sham Therapy

First Posted Date: 2017-05-24

Last Posted Date: 2017-05-24

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 22

Registration Number: NCT03165318

Locations: 🇸🇬
National University Health System, Singapore, Singapore

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

Phase 2

Conditions: NPC
Refractory Tumor

Interventions: Drug: OPB-111077

First Posted Date: 2017-05-18

Last Posted Date: 2017-06-15

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 52

Registration Number: NCT03158324

Locations: 🇸🇬
National University Hospital, Singapore, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy